Veralox Therapeutics is focused on developing first-in-class small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes, which each impact hundreds of thousands of new U.S. patients each year. Based on an understanding of the molecular mechanisms of these diseases, Veralox’s new treatment paradigms will lead to better outcomes for patients.